Abstract: Slide Presentations |

Infliximab (Remicade) Is Effective In Controlling Multisystem Sarcoidosis: A Report Of 10 Patients FREE TO VIEW

Shahriar Ghodsian, MD*; Violeta Yakimova, MD; Om P. Sharma, MD; C. T. Boylan, MD; Amir Radfar, MD
Author and Funding Information

Keck School of Medicine, Los Angeles, CA


Chest. 2004;126(4_MeetingAbstracts):742S. doi:10.1378/chest.126.4_MeetingAbstracts.742S-a
Text Size: A A A
Published online


PURPOSE:  Sarcoidosis is a chronic granulomatous disease in which primary cytokine tumor necrosis factor (TNF)-alpha plays a major role in perpetuating the inflamation. Corticosteroids, antimalerials, immunosupperssive agents, thalidomide, and pentoxifylline have been used to control the disease. We used infliximab (Remicade) in ten patients with sarcoidosis who had earlier developed severe side-effects or responded poorly to traditional treatment.

METHODS:  Ten patients with biopsy proven multisystem sarcoidosis selected for infliximab therapy include 7 women and 3 men. The group comprised of 6 Caucasians, 3 African-Americans, and 1 Hispanic. The duration of sarcoidosis varied from 3 to 37 years. Eight patients had chronic skin lesions, 3 patients had pulmonary involvement and 2 patients had neurosarcoidosis. Hypercalcemia and peripheral lymphadenopathy occurred in 1 patient.

RESULTS:  All patients treated with infliximab showed objective evidence of improvement. One patient developed plasma cell dyscrasia after showing a marked improvement of her sarcoidosis after six infusions.

CONCLUSION:  Infliximab is an effective treatment for patients with refractory sarcoidosis of skin, central nervous system, bones, lungs, and herpercalcemia. The long-term effects of the drug are not known. The drug may reactivate latent tuberculosis. The relationship with plasma cell dyscrasias and lymphoproliferative diseases remains unexplained.

CLINICAL IMPLICATIONS:  Infliximab may be used as an effective therapeutic agent for patients with sarcoidosis who are refractory to traditional treatment options.

DISCLOSURE:  S. Ghodsian, None.

Tuesday, October 26, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Managing fatigue in sarcoidosis - A systematic review of the evidence. Chron Respir Dis Published online Aug 9, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543